TY - JOUR AU - Rajshekhar Chakraborty, AU - Eli Muchtar, AU - Shaji K. Kumar, AU - Dragan Jevremovic, AU - Francis K. Buadi, AU - David Dingli, AU - Angela Dispenzieri, AU - Suzanne R. Hayman, AU - William J. Hogan, AU - Prashant Kapoor, AU - Martha Q. Lacy, AU - Nelson Leung, AU - Morie A. Gertz, PY - 2017/07/31 Y2 - 2024/03/29 TI - Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation JF - Haematologica JA - haematol VL - 102 IS - 8 SE - Articles DO - 10.3324/haematol.2017.166629 UR - https://haematologica.org/article/view/8164 SP - 1439-1445 AB - Circulating plasma cells at diagnosis, prior to auto-transplant and at relapse have a negative impact on survival in multiple myeloma. However, the impact of kinetics of circulating plasma cells along the course of illness has not been defined. We have analyzed 247 newly diagnosed multiple myeloma patients undergoing early auto-transplant who had paired evaluation of circulating plasma cells at diagnosis and pre-transplant by 6-color flow cytometry. A total of 117 patients had no detectable circulating plasma cells at both time points (CPC−/−), 82 had circulating plasma cells at diagnosis followed by complete eradication after induction (CPC+/−) and 48 had circulating plasma cells at transplant, including persistence of cells (CPC+/+; n=45) or emergence of new cells (CPC−/+; n=3) after induction. The rate of post-transplant stringent complete response was 32% in the CPC−/−, 30% in CPC+/− and 12% in CPC+/+ or −/+ groups (P=0.018). At a median follow up of 58 months from transplantation, the median progression-free survival in the 3 respective groups were 30, 24 and 14 months, and the 5-year overall survival rates were 83%, 70% and 43% (P